Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Fingolimod on Neurodegeneration, Brain Atrophy and Cognitive Impairment in Relapsing Remitting Multiple Sclerosis Patients

NCT02575365 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT02575365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02575365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Fingolimod on Neurodegeneration, Brain Atrophy and Cognitive Impairment in Relapsing Remitting Multiple Sclerosis Patients
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 4
Overall status
Terminated
Start date
February 16, 2016
Completion date
January 27, 2017
Enrollment
4 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

brain volume loss, cognition